Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net loss	$ (89,298)	$ (111,566)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,245	1,371
Stock-based compensation	13,103	7,905
Research and development license expense		3,500
Change in fair value of warrant liability	(16)	34,718
Issuance costs for pre-funded warrant liability		2,567
Non-cash loss on debt extinguishment		1,366
Non-cash change in fair value of term loan	(597)	1,278
Impairment of long-lived assets	4,838	1,065
Debt issuance costs expensed under the fair value option		867
Non-cash lease expense	1,217	1,182
Other	750	741
Changes in operating assets and liabilities:
Prepaid expenses and other assets	207	6,011
Accounts payable	(2,920)	(2,295)
Accrued expenses and other liabilities	(1,421)	(6,277)
Deferred revenue	(8,333)	(15,451)
Net cash used in operating activities	(81,225)	(73,018)
Cash flows from investing activities
Purchase of research and development license		(3,500)
Purchase of property, plant and equipment	(374)	(3,869)
Other	11	17
Net cash used in investing activities	(363)	(7,352)
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs	76,780
Debt issuance costs for term loan	(18)	(399)
Repayment of SVB term loan		(43,000)
Proceeds from Trinity term loan, net		39,550
Proceeds from issuance of common stock and pre-funded warrants from private placement, net of placement agent commissions and other offering costs		140,290
Proceeds from issuance of common stock from private placement		500
Payment of shelf registration costs		(387)
Proceeds from common stock issuances under ESPP	89	68
Other	(167)	(229)
Net cash provided by financing activities	76,684	136,393
Net (decrease) increase in cash, cash equivalents and restricted cash	(4,904)	56,023
Cash, cash equivalents and restricted cash at the beginning of the period	146,540	90,517
Cash, cash equivalents and restricted cash at the end of the period	141,636	146,540
Cash and cash equivalents	139,036	143,940
Restricted cash	2,600	2,600
Supplemental disclosure of cash flow information:
Cash paid for interest	5,282	4,952
Supplemental disclosure of noncash investing and financing activities:
Reclassification of warrants to additional paid-in capital		74,342
Allocation of proceeds to Success Fee liability		770
Recognition of asset retirement obligation		449
Issuance of warrants in connection with private placement		252
Property, plant and equipment in accounts payable and accrued expenses	346
Offering costs not yet paid	$ 46	$ 18